Riboxin®  (Inosine) is a metabolic agent, a precursor of adenosine triphosphate (ATP).

Inosine is an important nucleoside that is essential for proper translation of the genetic code in wobble base pairs. It provides antihypoxic, metabolic and antiarrhythmic effect. It increases the energy balance of the myocardium, improves the coronary blood flow and prevents consequences of intraoperative renal ischemia. The drug participates in the glucose metabolism and promotes metabolism activation under hypoxia and in the absence of ATP.

Indications for use:

  • coronary heart disease,
  • myocardial dystrophy,
  • myocardial infarction and heart rhythm disturbances
  • hepatitis,
  • cirrhosis,
  • fatty degeneration of the liver caused by alcohol or drugs, and urocoproporphyria. 

After ingestion, inosine is metabolized into uric acid, which has been suggested to be a natural antioxidant and peroxynitrite scavenger with potential benefits to patients with multiple sclerosis (MS) and Parkinson's. Patients with the highest serum urate levels had slower progression of Parkinson's symptoms. Inosine also is a popular ingredient in some fitness supplements.


Dosage and Administration:


During or before meals. The maximum daily dose of the drug is 0.6 - 2.4 g. In the first days of treatment, the daily dose is 0.6 - 0.8 g (0.2 g 3-4 times a day). In case of good tolerability of the drug, during the next 2 - 3 days the dose is increased up to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g per day. The duration of the course is from 4 weeks to 1.5 - 3 months.


The drug is used intravenously slowly, by stream or by drop infusion (40-60 drops per 1 minute). The treatment is commenced with an administration of 200 mg (10 ml of 20 mg / ml solution) once a day, then, in case of good tolerability, the dose is increased to 400 mg (20 ml of 20 mg /ml solution) 1 -2 times a day. The duration of treatment is 10-15 days. The stream infusion of the drug is possible in case of acute cardiac rhythm disturbance in a single dose of 200-400 mg (10-20 ml of 20 mg / ml).

For pharmacological protection of ischemic kidneys, Riboxin is injected intravenously by stream infusion in a single dose of 1,200 mg (60 ml of 20 mg / ml solution) 5-15 minutes before clamping of the renal artery, and then 800 mg more (40 ml of 20 mg / ml solution) immediately after the restoration of the blood flow. 

For intravenous injection by drop infusion, 20 mg / ml solution is diluted in 5% dextrose (glucose) solution or 0.9% sodium chloride solution (up to 250 ml).


  • hypersensitivity to the drug,
  • podagra,
  • hyperuricemia,
  • pregnancy and breastfeeding,
  • children under 18 years old.

Use with caution in renal failure.

Side effects

Allergic reactions: urticaria, skin itching, dermahemia (the drug should be discontinued).
When taking the drug, there can rarely be an increase in the concentration of uric acid in the blood and exacerbation of gout (in case of a prolonged use in high doses).